All News

Combining omega-3 supplements with exercise enhances immune response and alleviates tooth infections, offering new insights into managing apical periodontitis.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Accurate utility estimates are critical to providing a comprehensive view of quality of life for children impacted by pneumococcal disease.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Step up and speak out to break down barriers to health care and address social determinants of health.

New research reveals a significant link between type 2 diabetes, obesity, and fatty liver disease.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

The FDA approves garadacimab-gxii, a treatment for hereditary angioedema (HAE), offering convenient monthly self-injections for patients 12 years and older.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

The authors note that the combinatorial principal component analysis (cPCA) may be effective in other complex diseases outside of chronic kidney disease (CKD).

Clostridioides difficile (C difficile) represents a serious public health threat, with pharmacists and advocacy organizations playing critical roles in prevention, education, and management.

This single-center, descriptive, retrospective chart review identified barriers to outpatient chemotherapy use, revealing avoidable inpatient stays and highlighting targets for stewardship interventions.

The opportunity to optimize all medications, not just those that require a prescription, is long overdue.

Eli Lilly is expanding access to tirzepatide, a groundbreaking GLP-1 medication for weight management, offering more affordable options for obesity treatment.

Discover the latest FDA-approved treatments, including Dupixent for chronic urticaria and Valtoco for seizure clusters, enhancing patient care options.

Host Craig Beavers chats with Shannon Finks, PharmD, FCCP, BCPS, BCCP, AHSCP-CHC, president and director of pharmacy services at ZupMed in Memphis, Tennessee.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Talquetamab and teclistamab showed significant promise in a phase 1b/2 dose escalation and expansion trial.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Nemolizumab shows promising long-term efficacy in reducing itch and skin lesions for atopic dermatitis, enhancing quality of life for patients.

Bispecific therapies require clearer terminology to improve safety and communication.

The subcutaneous infusion is indicated for pediatric patients aged 6 to 17 years who weigh less than 60 kg.

New executive orders and legislation aim to lower prescription drug costs and enhance access to pharmacist services for seniors across the US.

Explore the evolving role of pharmacists in patient care, emphasizing personalized services, community health, and innovative solutions for better health outcomes.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, co-chair of the 2025 Oncology Pharmacists Connect (OPC) meeting, discusses what makes the event unique, highlights key sessions, and shares her excitement for the educational and networking opportunities.

Manish Agrawal, MD, discusses emerging research on psychedelic-assisted therapy for patients with cancer, including innovative dyadic treatment models, challenges in capturing meaningful outcomes, and growing interest in integrating psychedelics into oncology and palliative care.

Moderna's mRNA-1345 vaccine gains FDA approval, enhancing protection against RSV for high-risk adults aged 18 to 59 years, following earlier approvals for older populations.